You may contact Beigene South Africa by emailing infosa@beigene.co.za or call the toll-free line 0800 983 530
You can request further medical information on our products by emailing our dedicated medical information team at: https://www.beigenemedical.com.
You can request further medical information on our products by emailing our dedicated medical information team at: PatientSafetyZA@beigene.com. Please include your full name, professional designation, contact information, and specific questions or details about the information you are seeking. This will help us provide you with the most accurate and relevant information in a timely manner.
You may request information on BeiGene medicines approved in South Africa by emailing infosa@beigene.com
To ensure an efficient response kindly be specific on the detail of information required.
BeiGene is a global oncology company known for discovering and developing innovative oncology medicines that are affordable and accessible to far more patients worldwide.
BeiGene has one of the world’s largest oncology research teams and a broad and deep pipeline with the potential to address 80% of the world’s cancers by type. BeiGene’s small molecule inhibitor of Bruton’s tyrosine kinase (BTK), is approved for the treatment of various B-cell malignancies in 70 markets across the world.
BeiGene’s humanized monoclonal antibody directed against the immune checkpoint receptor PD-1, is approved for the treatment of various solid tumors across the world.
BeiGene is also known for collaborating with biopharmaceutical companies, including Amgen, Bristol Myers Squibb for Celgene, and Novartis, to develop and commercialize cancer therapies.
BeiGene is traded on three major exchanges – the NASDAQ, the Hong Kong Stock Exchange, and the Shanghai Stock Exchange.
For more information, visit the Stock Information page on the BeiGene website – link here.
BeiGene has offices and operations located across Asia, Australia, Europe, Latin America, and North America. The company’s administrative offices are in Basel, Beijing, and Cambridge, Mass.
BeiGene is a publicly traded global oncology company. BeiGene had its IPO on the NASDAQ in February 2016, and is currently traded on the NASDAQ, the Hong Kong Stock Exchange, and the Shanghai Stock Exchange. Amgen, Baker Brothers Advisors, and Capital International Investors are the top three holders of BeiGene.